Clinical Trial: Low-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy
Study Status: Not yet recruiting
Recruit Status: Not yet recruiting
Study Type: Interventional
Official Title: Low-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy: A Randomized Open Controlled Study
Brief Summary: Several studies have been showed that rifaximin can improve cognitive functions, driving simulator performance and health-related quality of life in patients with minimal hepatic encephalopathy. The aim of this prospective randomized open controlled study was to evaluate the efficacy and safety of rifaximin at different doses for the treatment of covert hepatic encephalopathy.
Detailed Summary:
Sponsor: Shanghai Changzheng Hospital
Current Primary Outcome:
- Percentage of patients showing covert hepatic encephalopathy reversal [ Time Frame: up to 6 months ]the percentage of patients showing covert hepatic encephalopathy reversal
- health-related quality of life improvement [ Time Frame: up to 6 month ]complete the questionnaire "sickness impact profile"
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Shanghai Changzheng Hospital
Dates:
Date Received: January 30, 2017
Date Started: May 1, 2017
Date Completion: March 31, 2018
Last Updated: March 6, 2017
Last Verified: March 2017
